[HTML][HTML] Remdesivir for the treatment of COVID‐19
F Grundeis, K Ansems, K Dahms… - … of systematic reviews, 2023 - ncbi.nlm.nih.gov
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
Remdesivir for the treatment of COVID‐19
Cochrane Haematology Group… - Cochrane Database …, 1996 - cochranelibrary.com
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …
Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview
M Mohseni, H Ameri, M Arab-Zozani - Frontiers in Medicine, 2022 - frontiersin.org
Background Although several studies have assessed the safety, efficacy, and effectiveness
of interventions in treating the COVID-19, many of them have limitations that can have an …
of interventions in treating the COVID-19, many of them have limitations that can have an …
Remdesivir efficacy and tolerability in children with COVID-19-associated allergic comorbidities such as asthma, allergic rhinitis, and atopic dermatitis
G Jugulete, M Luminos, C Pavelescu, MM Merișescu - Children, 2023 - mdpi.com
In children, coronavirus disease 2019 (COVID-19) starts as a minor illness compared to
adults, but during the ongoing COVID-19 pandemic, distinct SARS-CoV-2 variants and …
adults, but during the ongoing COVID-19 pandemic, distinct SARS-CoV-2 variants and …
Peptidic defective interfering gene nanoparticles against Omicron, Delta SARS-CoV-2 variants and influenza A virus in vivo
H Zhao, C Zhang, H Lam, X Meng, Z Peng… - … and Targeted Therapy, 2022 - nature.com
Defective interfering genes (DIGs) are short viral genomes and interfere with wild-type viral
replication. Here, we demonstrate that the new designed SARS-CoV-2 DIG (CD3600) can …
replication. Here, we demonstrate that the new designed SARS-CoV-2 DIG (CD3600) can …
Mortality in SARS-CoV-2 hospitalized patients treated with remdesivir: a nationwide, registry-based study in Italy
P Russo, E Tacconelli, PP Olimpieri, S Celant… - Viruses, 2022 - mdpi.com
Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …
recommending its use for the treatment of moderate-to-severe disease is still controversial …
Remdesivir for Treatment of Coronavirus Disease 2019 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies
Background Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of
coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical …
coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical …
Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development
P Ghasemiyeh, S Mohammadi-Samani - Virology Journal, 2024 - Springer
About four years have passed since the detection of the first cases of COVID-19 in China.
During this lethal pandemic, millions of people have lost their lives around the world. Since …
During this lethal pandemic, millions of people have lost their lives around the world. Since …
Pitfalls in reporting sample size calculation across randomized controlled trials involving ivermectin for the treatment of COVID-19
To the Editor: Since the outbreak of coronavirus disease 2019 (COVID-19), morbidity and
mortality continue to increase worldwide. 1 Several drugs have been developed/repurposed …
mortality continue to increase worldwide. 1 Several drugs have been developed/repurposed …
Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center …
D Yang, M Ju, H Wang, Y Jia, X Wang, H Fang… - BMC Pharmacology and …, 2023 - Springer
Background The rapid worldwide spread of COVID-19 has caused a global health challenge
with high mortality of severe or critically ill patients with COVID-19. To date, there is no …
with high mortality of severe or critically ill patients with COVID-19. To date, there is no …